nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—CYP3A4—Calcitriol—psoriasis	0.0656	0.191	CbGbCtD
Fulvestrant—CYP3A4—Methoxsalen—psoriasis	0.051	0.149	CbGbCtD
Fulvestrant—CYP3A4—Cholecalciferol—psoriasis	0.0338	0.0986	CbGbCtD
Fulvestrant—CYP3A4—Mycophenolate mofetil—psoriasis	0.0293	0.0855	CbGbCtD
Fulvestrant—CYP3A4—Triamcinolone—psoriasis	0.0293	0.0855	CbGbCtD
Fulvestrant—CYP3A4—Betamethasone—psoriasis	0.0251	0.0733	CbGbCtD
Fulvestrant—CYP3A4—Prednisolone—psoriasis	0.0248	0.0724	CbGbCtD
Fulvestrant—CYP3A4—Hydrocortisone—psoriasis	0.0235	0.0686	CbGbCtD
Fulvestrant—CYP3A4—Prednisone—psoriasis	0.0234	0.0683	CbGbCtD
Fulvestrant—CYP3A4—Cyclosporine—psoriasis	0.0222	0.0648	CbGbCtD
Fulvestrant—CYP3A4—Dexamethasone—psoriasis	0.0146	0.0427	CbGbCtD
Fulvestrant—NR1H4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00642	0.0382	CbGpPWpGaD
Fulvestrant—ESRRA—Transcriptional activation of mitochondrial biogenesis—CARM1—psoriasis	0.0054	0.0321	CbGpPWpGaD
Fulvestrant—NR1H4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.0052	0.031	CbGpPWpGaD
Fulvestrant—NR1H4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00513	0.0306	CbGpPWpGaD
Fulvestrant—ESRRA—Mitochondrial biogenesis—CARM1—psoriasis	0.00467	0.0278	CbGpPWpGaD
Fulvestrant—EPHX2—Metapathway biotransformation—CYP2S1—psoriasis	0.00467	0.0278	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptors—VDR—psoriasis	0.00369	0.022	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.00365	0.0217	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00295	0.0175	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptor transcription pathway—VDR—psoriasis	0.00292	0.0174	CbGpPWpGaD
Fulvestrant—NR1H4—Biological oxidations—CYP2S1—psoriasis	0.00276	0.0164	CbGpPWpGaD
Fulvestrant—ESR2—Ovarian Infertility Genes—VDR—psoriasis	0.0027	0.016	CbGpPWpGaD
Fulvestrant—ESRRA—PPARA activates gene expression—CARM1—psoriasis	0.00264	0.0157	CbGpPWpGaD
Fulvestrant—ESRRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00259	0.0154	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptors—PPARG—psoriasis	0.00257	0.0153	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.00255	0.0152	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—IL23A—psoriasis	0.00255	0.0152	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptors—VDR—psoriasis	0.00235	0.014	CbGpPWpGaD
Fulvestrant—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00221	0.0132	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—VDR—psoriasis	0.00213	0.0127	CbGpPWpGaD
Fulvestrant—ESRRA—Organelle biogenesis and maintenance—CARM1—psoriasis	0.00212	0.0126	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00206	0.0122	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00203	0.0121	CbGpPWpGaD
Fulvestrant—NR1H4—Orphan transporters—CARM1—psoriasis	0.00202	0.012	CbGpPWpGaD
Fulvestrant—NR1H4—PPARA activates gene expression—CARM1—psoriasis	0.00193	0.0115	CbGpPWpGaD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00189	0.0112	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—VDR—psoriasis	0.00186	0.011	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—TGFA—psoriasis	0.00183	0.0109	CbGpPWpGaD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.00178	0.0106	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptors—PPARG—psoriasis	0.00164	0.00975	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.0015	0.0089	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00149	0.00884	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.00141	0.00837	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen Receptor Pathway—JUN—psoriasis	0.00138	0.00822	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.00137	0.00818	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.00135	0.00805	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.0013	0.00775	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00129	0.0077	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—TARS—psoriasis	0.00129	0.00768	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.00127	0.00758	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen Receptor Pathway—STAT3—psoriasis	0.0012	0.00711	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—VDR—psoriasis	0.00118	0.00705	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL13—psoriasis	0.00118	0.00702	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—REL—psoriasis	0.00117	0.00696	CbGpPWpGaD
Fulvestrant—ESRRA—PPARA activates gene expression—PPARG—psoriasis	0.0011	0.00654	CbGpPWpGaD
Fulvestrant—ESRRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.00108	0.0064	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.00102	0.00608	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—NDUFA5—psoriasis	0.000952	0.00566	CbGpPWpGaD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000944	0.00561	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—TARS—psoriasis	0.000944	0.00561	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000936	0.00557	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000919	0.00547	CbGpPWpGaD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000907	0.0054	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000887	0.00528	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen signaling pathway—JUN—psoriasis	0.000875	0.00521	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—CARM1—psoriasis	0.000844	0.00502	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen signaling pathway—NFKB1—psoriasis	0.000843	0.00501	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—PPARG—psoriasis	0.000826	0.00491	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—TARS—psoriasis	0.000822	0.00489	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP2S1—psoriasis	0.000809	0.00482	CbGpPWpGaD
Fulvestrant—NR1H4—PPARA activates gene expression—PPARG—psoriasis	0.000804	0.00478	CbGpPWpGaD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000787	0.00468	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	0.000766	0.00456	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—NDUFA5—psoriasis	0.000761	0.00453	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000745	0.00443	CbGpPWpGaD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000742	0.00441	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000738	0.00439	CbGpPWpGaD
Fulvestrant—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000735	0.00437	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000709	0.00422	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000709	0.00422	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL10—psoriasis	0.000707	0.00421	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.000693	0.00412	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL4—psoriasis	0.000688	0.00409	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000653	0.00388	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYP2S1—psoriasis	0.000647	0.00385	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000647	0.00385	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000629	0.00374	CbGpPWpGaD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000626	0.00372	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—HLA-A—psoriasis	0.000623	0.00371	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—NOS2—psoriasis	0.000621	0.0037	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—CARM1—psoriasis	0.000617	0.00367	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000573	0.00341	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NDUFA5—psoriasis	0.000556	0.00331	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—LEP—psoriasis	0.00055	0.00327	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000542	0.00322	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—CARM1—psoriasis	0.000537	0.0032	CbGpPWpGaD
Fulvestrant—ESR1—FOXA1 transcription factor network—JUN—psoriasis	0.000521	0.0031	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000518	0.00308	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—CP—psoriasis	0.000517	0.00307	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—VDR—psoriasis	0.000504	0.003	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—CARM1—psoriasis	0.000493	0.00293	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000484	0.00288	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000481	0.00287	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—IFNG—psoriasis	0.000477	0.00284	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP2S1—psoriasis	0.000473	0.00281	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—CXCL8—psoriasis	0.000443	0.00264	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000439	0.00261	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—IFNG—psoriasis	0.000425	0.00253	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000424	0.00252	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000422	0.00251	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Prednisolone—psoriasis	0.000419	0.000857	CcSEcCtD
Fulvestrant—Nausea—Hydroxyurea—psoriasis	0.000417	0.000854	CcSEcCtD
Fulvestrant—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000417	0.000853	CcSEcCtD
Fulvestrant—Pruritus—Mycophenolic acid—psoriasis	0.000416	0.000852	CcSEcCtD
Fulvestrant—Myalgia—Triamcinolone—psoriasis	0.000416	0.00085	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—IFNG—psoriasis	0.000416	0.00247	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Hydrocortisone—psoriasis	0.000415	0.000849	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—TARS—psoriasis	0.000414	0.00247	CbGpPWpGaD
Fulvestrant—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000414	0.000847	CcSEcCtD
Fulvestrant—Decreased appetite—Cyclosporine—psoriasis	0.000414	0.000846	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000413	0.00246	CbGpPWpGaD
Fulvestrant—Infestation NOS—Methotrexate—psoriasis	0.000413	0.000844	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—psoriasis	0.000413	0.000844	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—JUN—psoriasis	0.000412	0.00245	CbGpPWpGaD
Fulvestrant—Depression—Methotrexate—psoriasis	0.000411	0.000841	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000411	0.000841	CcSEcCtD
Fulvestrant—Skin disorder—Hydrocortisone—psoriasis	0.000411	0.000841	CcSEcCtD
Fulvestrant—Fatigue—Cyclosporine—psoriasis	0.000411	0.000839	CcSEcCtD
Fulvestrant—Hyperhidrosis—Hydrocortisone—psoriasis	0.000409	0.000837	CcSEcCtD
Fulvestrant—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000409	0.000836	CcSEcCtD
Fulvestrant—Constipation—Cyclosporine—psoriasis	0.000407	0.000833	CcSEcCtD
Fulvestrant—Pain—Cyclosporine—psoriasis	0.000407	0.000833	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—CARM1—psoriasis	0.000406	0.00242	CbGpPWpGaD
Fulvestrant—Angioedema—Dexamethasone—psoriasis	0.000405	0.000828	CcSEcCtD
Fulvestrant—Angioedema—Betamethasone—psoriasis	0.000405	0.000828	CcSEcCtD
Fulvestrant—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000404	0.000826	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000404	0.0024	CbGpPWpGaD
Fulvestrant—Anorexia—Hydrocortisone—psoriasis	0.000403	0.000825	CcSEcCtD
Fulvestrant—Diarrhoea—Mycophenolic acid—psoriasis	0.000403	0.000824	CcSEcCtD
Fulvestrant—Angiopathy—Prednisone—psoriasis	0.000402	0.000822	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000401	0.00082	CcSEcCtD
Fulvestrant—Immune system disorder—Prednisone—psoriasis	0.0004	0.000819	CcSEcCtD
Fulvestrant—Vertigo—Dexamethasone—psoriasis	0.000398	0.000814	CcSEcCtD
Fulvestrant—Vertigo—Betamethasone—psoriasis	0.000398	0.000814	CcSEcCtD
Fulvestrant—Pain—Mycophenolate mofetil—psoriasis	0.000397	0.000812	CcSEcCtD
Fulvestrant—Constipation—Mycophenolate mofetil—psoriasis	0.000397	0.000812	CcSEcCtD
Fulvestrant—Infection—Triamcinolone—psoriasis	0.000396	0.00081	CcSEcCtD
Fulvestrant—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000396	0.00235	CbGpPWpGaD
Fulvestrant—Sweating—Methotrexate—psoriasis	0.000396	0.000809	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CARM1—psoriasis	0.000395	0.00235	CbGpPWpGaD
Fulvestrant—Insomnia—Prednisolone—psoriasis	0.000392	0.000801	CcSEcCtD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.00039	0.00232	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Methotrexate—psoriasis	0.00039	0.000798	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Cyclosporine—psoriasis	0.000389	0.000796	CcSEcCtD
Fulvestrant—Dizziness—Mycophenolic acid—psoriasis	0.000389	0.000796	CcSEcCtD
Fulvestrant—Paraesthesia—Prednisolone—psoriasis	0.000389	0.000796	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CXCL8—psoriasis	0.000387	0.0023	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	0.000386	0.0023	CbGpPWpGaD
Fulvestrant—Malnutrition—Prednisone—psoriasis	0.000386	0.000789	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000386	0.000788	CcSEcCtD
Fulvestrant—Hyperhidrosis—Triamcinolone—psoriasis	0.000385	0.000788	CcSEcCtD
Fulvestrant—Insomnia—Hydrocortisone—psoriasis	0.000383	0.000783	CcSEcCtD
Fulvestrant—Paraesthesia—Hydrocortisone—psoriasis	0.00038	0.000777	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00038	0.000777	CcSEcCtD
Fulvestrant—Urticaria—Cyclosporine—psoriasis	0.000378	0.000774	CcSEcCtD
Fulvestrant—Myalgia—Betamethasone—psoriasis	0.000377	0.000771	CcSEcCtD
Fulvestrant—Myalgia—Dexamethasone—psoriasis	0.000377	0.000771	CcSEcCtD
Fulvestrant—Abdominal pain—Cyclosporine—psoriasis	0.000376	0.00077	CcSEcCtD
Fulvestrant—Body temperature increased—Cyclosporine—psoriasis	0.000376	0.00077	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000376	0.00224	CbGpPWpGaD
Fulvestrant—Anxiety—Betamethasone—psoriasis	0.000376	0.000769	CcSEcCtD
Fulvestrant—Anxiety—Dexamethasone—psoriasis	0.000376	0.000769	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—JUN—psoriasis	0.000375	0.00223	CbGpPWpGaD
Fulvestrant—Vomiting—Mycophenolic acid—psoriasis	0.000374	0.000765	CcSEcCtD
Fulvestrant—Dyspepsia—Hydrocortisone—psoriasis	0.000373	0.000762	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—psoriasis	0.000372	0.000761	CcSEcCtD
Fulvestrant—Rash—Mycophenolic acid—psoriasis	0.000371	0.000759	CcSEcCtD
Fulvestrant—Dermatitis—Mycophenolic acid—psoriasis	0.000371	0.000758	CcSEcCtD
Fulvestrant—Pain—Prednisolone—psoriasis	0.000371	0.000758	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—psoriasis	0.00037	0.000757	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—psoriasis	0.00037	0.000757	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000369	0.0022	CbGpPWpGaD
Fulvestrant—Urticaria—Mycophenolate mofetil—psoriasis	0.000369	0.000755	CcSEcCtD
Fulvestrant—Headache—Mycophenolic acid—psoriasis	0.000369	0.000754	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—VDR—psoriasis	0.000368	0.00219	CbGpPWpGaD
Fulvestrant—Decreased appetite—Hydrocortisone—psoriasis	0.000368	0.000752	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—JUN—psoriasis	0.000368	0.00219	CbGpPWpGaD
Fulvestrant—Pharyngitis—Methotrexate—psoriasis	0.000368	0.000752	CcSEcCtD
Fulvestrant—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000367	0.000751	CcSEcCtD
Fulvestrant—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000367	0.000751	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000365	0.000747	CcSEcCtD
Fulvestrant—Fatigue—Hydrocortisone—psoriasis	0.000365	0.000746	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000363	0.000742	CcSEcCtD
Fulvestrant—Pain—Hydrocortisone—psoriasis	0.000362	0.00074	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000361	0.00215	CbGpPWpGaD
Fulvestrant—Insomnia—Triamcinolone—psoriasis	0.00036	0.000737	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—JUN—psoriasis	0.000359	0.00214	CbGpPWpGaD
Fulvestrant—Infection—Dexamethasone—psoriasis	0.000359	0.000735	CcSEcCtD
Fulvestrant—Infection—Betamethasone—psoriasis	0.000359	0.000735	CcSEcCtD
Fulvestrant—Paraesthesia—Triamcinolone—psoriasis	0.000358	0.000732	CcSEcCtD
Fulvestrant—Anaemia—Prednisone—psoriasis	0.000357	0.000729	CcSEcCtD
Fulvestrant—Dyspnoea—Triamcinolone—psoriasis	0.000355	0.000726	CcSEcCtD
Fulvestrant—Nervous system disorder—Dexamethasone—psoriasis	0.000355	0.000725	CcSEcCtD
Fulvestrant—Nervous system disorder—Betamethasone—psoriasis	0.000355	0.000725	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—NFKB1—psoriasis	0.000354	0.00211	CbGpPWpGaD
Fulvestrant—Angioedema—Prednisone—psoriasis	0.000353	0.000721	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—PPARG—psoriasis	0.000351	0.00209	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Cyclosporine—psoriasis	0.000351	0.000717	CcSEcCtD
Fulvestrant—Dyspepsia—Triamcinolone—psoriasis	0.000351	0.000717	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—TP53—psoriasis	0.00035	0.00208	CbGpPWpGaD
Fulvestrant—Nausea—Mycophenolic acid—psoriasis	0.00035	0.000715	CcSEcCtD
Fulvestrant—Hyperhidrosis—Dexamethasone—psoriasis	0.00035	0.000715	CcSEcCtD
Fulvestrant—Hyperhidrosis—Betamethasone—psoriasis	0.00035	0.000715	CcSEcCtD
Fulvestrant—Vertigo—Prednisone—psoriasis	0.000347	0.000709	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000346	0.000708	CcSEcCtD
Fulvestrant—Anorexia—Dexamethasone—psoriasis	0.000345	0.000705	CcSEcCtD
Fulvestrant—Anorexia—Betamethasone—psoriasis	0.000345	0.000705	CcSEcCtD
Fulvestrant—Urticaria—Prednisolone—psoriasis	0.000344	0.000704	CcSEcCtD
Fulvestrant—Fatigue—Triamcinolone—psoriasis	0.000344	0.000703	CcSEcCtD
Fulvestrant—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000342	0.0007	CcSEcCtD
Fulvestrant—Asthenia—Cyclosporine—psoriasis	0.000342	0.000699	CcSEcCtD
Fulvestrant—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000341	0.00203	CbGpPWpGaD
Fulvestrant—Pain—Triamcinolone—psoriasis	0.000341	0.000697	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000339	0.00202	CbGpPWpGaD
Fulvestrant—Pruritus—Cyclosporine—psoriasis	0.000337	0.000689	CcSEcCtD
Fulvestrant—Urticaria—Hydrocortisone—psoriasis	0.000336	0.000687	CcSEcCtD
Fulvestrant—Angiopathy—Methotrexate—psoriasis	0.000336	0.000687	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—psoriasis	0.000335	0.000684	CcSEcCtD
Fulvestrant—Body temperature increased—Hydrocortisone—psoriasis	0.000335	0.000684	CcSEcCtD
Fulvestrant—Abdominal pain—Hydrocortisone—psoriasis	0.000335	0.000684	CcSEcCtD
Fulvestrant—Asthenia—Mycophenolate mofetil—psoriasis	0.000333	0.000682	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000329	0.000674	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000329	0.000674	CcSEcCtD
Fulvestrant—Pruritus—Mycophenolate mofetil—psoriasis	0.000329	0.000672	CcSEcCtD
Fulvestrant—Myalgia—Prednisone—psoriasis	0.000328	0.000672	CcSEcCtD
Fulvestrant—Arthralgia—Prednisone—psoriasis	0.000328	0.000672	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000328	0.00195	CbGpPWpGaD
Fulvestrant—Anxiety—Prednisone—psoriasis	0.000327	0.000669	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—NFKB1—psoriasis	0.000327	0.00195	CbGpPWpGaD
Fulvestrant—Insomnia—Betamethasone—psoriasis	0.000327	0.000669	CcSEcCtD
Fulvestrant—Insomnia—Dexamethasone—psoriasis	0.000327	0.000669	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000326	0.000667	CcSEcCtD
Fulvestrant—Diarrhoea—Cyclosporine—psoriasis	0.000326	0.000666	CcSEcCtD
Fulvestrant—Paraesthesia—Dexamethasone—psoriasis	0.000325	0.000664	CcSEcCtD
Fulvestrant—Paraesthesia—Betamethasone—psoriasis	0.000325	0.000664	CcSEcCtD
Fulvestrant—Malnutrition—Methotrexate—psoriasis	0.000322	0.000659	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—VDR—psoriasis	0.000321	0.00191	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	0.00032	0.0019	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Prednisolone—psoriasis	0.000319	0.000653	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000319	0.0019	CbGpPWpGaD
Fulvestrant—Dyspepsia—Betamethasone—psoriasis	0.000318	0.000651	CcSEcCtD
Fulvestrant—Dyspepsia—Dexamethasone—psoriasis	0.000318	0.000651	CcSEcCtD
Fulvestrant—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000318	0.00065	CcSEcCtD
Fulvestrant—Urticaria—Triamcinolone—psoriasis	0.000317	0.000647	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CARM1—psoriasis	0.000316	0.00188	CbGpPWpGaD
Fulvestrant—Body temperature increased—Triamcinolone—psoriasis	0.000315	0.000644	CcSEcCtD
Fulvestrant—Dizziness—Cyclosporine—psoriasis	0.000315	0.000644	CcSEcCtD
Fulvestrant—Decreased appetite—Betamethasone—psoriasis	0.000314	0.000643	CcSEcCtD
Fulvestrant—Decreased appetite—Dexamethasone—psoriasis	0.000314	0.000643	CcSEcCtD
Fulvestrant—Infection—Prednisone—psoriasis	0.000313	0.00064	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000312	0.000638	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Betamethasone—psoriasis	0.000312	0.000638	CcSEcCtD
Fulvestrant—Back pain—Methotrexate—psoriasis	0.000312	0.000638	CcSEcCtD
Fulvestrant—Hypersensitivity—Hydrocortisone—psoriasis	0.000312	0.000638	CcSEcCtD
Fulvestrant—Fatigue—Dexamethasone—psoriasis	0.000312	0.000637	CcSEcCtD
Fulvestrant—Fatigue—Betamethasone—psoriasis	0.000312	0.000637	CcSEcCtD
Fulvestrant—Pain—Betamethasone—psoriasis	0.000309	0.000632	CcSEcCtD
Fulvestrant—Pain—Dexamethasone—psoriasis	0.000309	0.000632	CcSEcCtD
Fulvestrant—Nervous system disorder—Prednisone—psoriasis	0.000309	0.000631	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000307	0.00183	CbGpPWpGaD
Fulvestrant—Dizziness—Mycophenolate mofetil—psoriasis	0.000307	0.000628	CcSEcCtD
Fulvestrant—Skin disorder—Prednisone—psoriasis	0.000306	0.000625	CcSEcCtD
Fulvestrant—Hyperhidrosis—Prednisone—psoriasis	0.000304	0.000622	CcSEcCtD
Fulvestrant—Asthenia—Hydrocortisone—psoriasis	0.000304	0.000621	CcSEcCtD
Fulvestrant—Vomiting—Cyclosporine—psoriasis	0.000303	0.000619	CcSEcCtD
Fulvestrant—Rash—Cyclosporine—psoriasis	0.0003	0.000614	CcSEcCtD
Fulvestrant—Anorexia—Prednisone—psoriasis	0.0003	0.000614	CcSEcCtD
Fulvestrant—Dermatitis—Cyclosporine—psoriasis	0.0003	0.000613	CcSEcCtD
Fulvestrant—Pruritus—Hydrocortisone—psoriasis	0.000299	0.000612	CcSEcCtD
Fulvestrant—Headache—Cyclosporine—psoriasis	0.000298	0.00061	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—psoriasis	0.000298	0.000609	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—CARM1—psoriasis	0.000297	0.00177	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Dexamethasone—psoriasis	0.000296	0.000605	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Betamethasone—psoriasis	0.000296	0.000605	CcSEcCtD
Fulvestrant—Vomiting—Mycophenolate mofetil—psoriasis	0.000295	0.000604	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000295	0.00176	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000294	0.00175	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—STAT3—psoriasis	0.000294	0.00175	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Triamcinolone—psoriasis	0.000294	0.0006	CcSEcCtD
Fulvestrant—Rash—Mycophenolate mofetil—psoriasis	0.000293	0.000599	CcSEcCtD
Fulvestrant—Dermatitis—Mycophenolate mofetil—psoriasis	0.000293	0.000598	CcSEcCtD
Fulvestrant—Headache—Mycophenolate mofetil—psoriasis	0.000291	0.000595	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—psoriasis	0.00029	0.000592	CcSEcCtD
Fulvestrant—Diarrhoea—Hydrocortisone—psoriasis	0.00029	0.000592	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000289	0.00172	CbGpPWpGaD
Fulvestrant—Leukopenia—Methotrexate—psoriasis	0.000289	0.00059	CcSEcCtD
Fulvestrant—Urticaria—Dexamethasone—psoriasis	0.000287	0.000587	CcSEcCtD
Fulvestrant—Urticaria—Betamethasone—psoriasis	0.000287	0.000587	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Prednisone—psoriasis	0.000287	0.000587	CcSEcCtD
Fulvestrant—Dizziness—Prednisolone—psoriasis	0.000287	0.000586	CcSEcCtD
Fulvestrant—Asthenia—Triamcinolone—psoriasis	0.000286	0.000585	CcSEcCtD
Fulvestrant—Body temperature increased—Betamethasone—psoriasis	0.000286	0.000584	CcSEcCtD
Fulvestrant—Body temperature increased—Dexamethasone—psoriasis	0.000286	0.000584	CcSEcCtD
Fulvestrant—Abdominal pain—Dexamethasone—psoriasis	0.000286	0.000584	CcSEcCtD
Fulvestrant—Abdominal pain—Betamethasone—psoriasis	0.000286	0.000584	CcSEcCtD
Fulvestrant—Insomnia—Prednisone—psoriasis	0.000285	0.000582	CcSEcCtD
Fulvestrant—Nausea—Cyclosporine—psoriasis	0.000283	0.000578	CcSEcCtD
Fulvestrant—Paraesthesia—Prednisone—psoriasis	0.000283	0.000578	CcSEcCtD
Fulvestrant—Pruritus—Triamcinolone—psoriasis	0.000282	0.000576	CcSEcCtD
Fulvestrant—Cough—Methotrexate—psoriasis	0.000281	0.000575	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—TNF—psoriasis	0.000281	0.00167	CbGpPWpGaD
Fulvestrant—Dizziness—Hydrocortisone—psoriasis	0.00028	0.000572	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000279	0.00166	CbGpPWpGaD
Fulvestrant—Dyspepsia—Prednisone—psoriasis	0.000277	0.000567	CcSEcCtD
Fulvestrant—Nausea—Mycophenolate mofetil—psoriasis	0.000276	0.000564	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—psoriasis	0.000275	0.000561	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—psoriasis	0.000275	0.000561	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—psoriasis	0.000275	0.000561	CcSEcCtD
Fulvestrant—Decreased appetite—Prednisone—psoriasis	0.000274	0.00056	CcSEcCtD
Fulvestrant—Rash—Prednisolone—psoriasis	0.000273	0.000559	CcSEcCtD
Fulvestrant—Dermatitis—Prednisolone—psoriasis	0.000273	0.000558	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000273	0.000557	CcSEcCtD
Fulvestrant—Fatigue—Prednisone—psoriasis	0.000271	0.000555	CcSEcCtD
Fulvestrant—Headache—Prednisolone—psoriasis	0.000271	0.000555	CcSEcCtD
Fulvestrant—ESR1—Generic Transcription Pathway—CARM1—psoriasis	0.000271	0.00161	CbGpPWpGaD
Fulvestrant—Constipation—Prednisone—psoriasis	0.000269	0.000551	CcSEcCtD
Fulvestrant—Vomiting—Hydrocortisone—psoriasis	0.000269	0.00055	CcSEcCtD
Fulvestrant—Rash—Hydrocortisone—psoriasis	0.000267	0.000546	CcSEcCtD
Fulvestrant—Dermatitis—Hydrocortisone—psoriasis	0.000267	0.000545	CcSEcCtD
Fulvestrant—Headache—Hydrocortisone—psoriasis	0.000265	0.000542	CcSEcCtD
Fulvestrant—Dizziness—Triamcinolone—psoriasis	0.000264	0.000539	CcSEcCtD
Fulvestrant—Infection—Methotrexate—psoriasis	0.000261	0.000535	CcSEcCtD
Fulvestrant—Asthenia—Betamethasone—psoriasis	0.000259	0.00053	CcSEcCtD
Fulvestrant—Asthenia—Dexamethasone—psoriasis	0.000259	0.00053	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—CARM1—psoriasis	0.000259	0.00154	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Methotrexate—psoriasis	0.000258	0.000528	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Prednisone—psoriasis	0.000258	0.000527	CcSEcCtD
Fulvestrant—Nausea—Prednisolone—psoriasis	0.000257	0.000526	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—PPARG—psoriasis	0.000257	0.00153	CbGpPWpGaD
Fulvestrant—Pruritus—Dexamethasone—psoriasis	0.000256	0.000523	CcSEcCtD
Fulvestrant—Pruritus—Betamethasone—psoriasis	0.000256	0.000523	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—psoriasis	0.000256	0.000523	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—psoriasis	0.000254	0.00052	CcSEcCtD
Fulvestrant—Vomiting—Triamcinolone—psoriasis	0.000253	0.000518	CcSEcCtD
Fulvestrant—Nausea—Hydrocortisone—psoriasis	0.000251	0.000514	CcSEcCtD
Fulvestrant—Rash—Triamcinolone—psoriasis	0.000251	0.000514	CcSEcCtD
Fulvestrant—Dermatitis—Triamcinolone—psoriasis	0.000251	0.000513	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—psoriasis	0.000251	0.000513	CcSEcCtD
Fulvestrant—Urticaria—Prednisone—psoriasis	0.00025	0.000511	CcSEcCtD
Fulvestrant—Headache—Triamcinolone—psoriasis	0.00025	0.00051	CcSEcCtD
Fulvestrant—Abdominal pain—Prednisone—psoriasis	0.000249	0.000509	CcSEcCtD
Fulvestrant—Body temperature increased—Prednisone—psoriasis	0.000249	0.000509	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—IL6—psoriasis	0.000249	0.00148	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000248	0.00147	CbGpPWpGaD
Fulvestrant—Diarrhoea—Betamethasone—psoriasis	0.000247	0.000506	CcSEcCtD
Fulvestrant—Diarrhoea—Dexamethasone—psoriasis	0.000247	0.000506	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CAT—psoriasis	0.000243	0.00145	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000243	0.00144	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—VDR—psoriasis	0.000243	0.00144	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—psoriasis	0.00024	0.00049	CcSEcCtD
Fulvestrant—Dizziness—Dexamethasone—psoriasis	0.000239	0.000489	CcSEcCtD
Fulvestrant—Dizziness—Betamethasone—psoriasis	0.000239	0.000489	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	0.000239	0.00142	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—TYK2—psoriasis	0.000239	0.00142	CbGpPWpGaD
Fulvestrant—Insomnia—Methotrexate—psoriasis	0.000238	0.000487	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—psoriasis	0.000237	0.00141	CbGpPWpGaD
Fulvestrant—Nausea—Triamcinolone—psoriasis	0.000237	0.000484	CcSEcCtD
Fulvestrant—Paraesthesia—Methotrexate—psoriasis	0.000236	0.000483	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—psoriasis	0.000235	0.00048	CcSEcCtD
Fulvestrant—Hypersensitivity—Prednisone—psoriasis	0.000232	0.000474	CcSEcCtD
Fulvestrant—Dyspepsia—Methotrexate—psoriasis	0.000232	0.000474	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—CARM1—psoriasis	0.000231	0.00137	CbGpPWpGaD
Fulvestrant—Vomiting—Betamethasone—psoriasis	0.00023	0.00047	CcSEcCtD
Fulvestrant—Vomiting—Dexamethasone—psoriasis	0.00023	0.00047	CcSEcCtD
Fulvestrant—Decreased appetite—Methotrexate—psoriasis	0.000229	0.000468	CcSEcCtD
Fulvestrant—Rash—Dexamethasone—psoriasis	0.000228	0.000466	CcSEcCtD
Fulvestrant—Rash—Betamethasone—psoriasis	0.000228	0.000466	CcSEcCtD
Fulvestrant—Dermatitis—Betamethasone—psoriasis	0.000228	0.000466	CcSEcCtD
Fulvestrant—Dermatitis—Dexamethasone—psoriasis	0.000228	0.000466	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Methotrexate—psoriasis	0.000227	0.000465	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—psoriasis	0.000227	0.000464	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL6—psoriasis	0.000227	0.00135	CbGpPWpGaD
Fulvestrant—Headache—Dexamethasone—psoriasis	0.000227	0.000463	CcSEcCtD
Fulvestrant—Headache—Betamethasone—psoriasis	0.000227	0.000463	CcSEcCtD
Fulvestrant—Asthenia—Prednisone—psoriasis	0.000226	0.000462	CcSEcCtD
Fulvestrant—Pain—Methotrexate—psoriasis	0.000225	0.00046	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—PPARG—psoriasis	0.000224	0.00133	CbGpPWpGaD
Fulvestrant—Pruritus—Prednisone—psoriasis	0.000223	0.000456	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—IL6—psoriasis	0.000217	0.00129	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000216	0.00128	CbGpPWpGaD
Fulvestrant—Diarrhoea—Prednisone—psoriasis	0.000215	0.000441	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methotrexate—psoriasis	0.000215	0.00044	CcSEcCtD
Fulvestrant—Nausea—Dexamethasone—psoriasis	0.000215	0.000439	CcSEcCtD
Fulvestrant—Nausea—Betamethasone—psoriasis	0.000215	0.000439	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	0.000211	0.00125	CbGpPWpGaD
Fulvestrant—Urticaria—Methotrexate—psoriasis	0.000209	0.000427	CcSEcCtD
Fulvestrant—Dizziness—Prednisone—psoriasis	0.000208	0.000426	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—psoriasis	0.000208	0.000425	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—psoriasis	0.000208	0.000425	CcSEcCtD
Fulvestrant—Vomiting—Prednisone—psoriasis	0.0002	0.000409	CcSEcCtD
Fulvestrant—Rash—Prednisone—psoriasis	0.000199	0.000406	CcSEcCtD
Fulvestrant—Dermatitis—Prednisone—psoriasis	0.000198	0.000406	CcSEcCtD
Fulvestrant—Headache—Prednisone—psoriasis	0.000197	0.000403	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CAT—psoriasis	0.000194	0.00116	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—JUN—psoriasis	0.000194	0.00116	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Methotrexate—psoriasis	0.000194	0.000396	CcSEcCtD
Fulvestrant—ESR1—Signaling Pathways—HCAR2—psoriasis	0.000192	0.00114	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—APOE—psoriasis	0.000189	0.00112	CbGpPWpGaD
Fulvestrant—Asthenia—Methotrexate—psoriasis	0.000189	0.000386	CcSEcCtD
Fulvestrant—Nausea—Prednisone—psoriasis	0.000187	0.000382	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.000187	0.00111	CbGpPWpGaD
Fulvestrant—Pruritus—Methotrexate—psoriasis	0.000186	0.000381	CcSEcCtD
Fulvestrant—Diarrhoea—Methotrexate—psoriasis	0.00018	0.000368	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—VDR—psoriasis	0.000177	0.00105	CbGpPWpGaD
Fulvestrant—Dizziness—Methotrexate—psoriasis	0.000174	0.000356	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.00017	0.00101	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PPARG—psoriasis	0.000169	0.00101	CbGpPWpGaD
Fulvestrant—Vomiting—Methotrexate—psoriasis	0.000167	0.000342	CcSEcCtD
Fulvestrant—ESR1—Signaling Pathways—TAGAP—psoriasis	0.000166	0.00099	CbGpPWpGaD
Fulvestrant—Rash—Methotrexate—psoriasis	0.000166	0.000339	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—psoriasis	0.000166	0.000339	CcSEcCtD
Fulvestrant—Headache—Methotrexate—psoriasis	0.000165	0.000337	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—PPARG—psoriasis	0.000165	0.000979	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—VDR—psoriasis	0.000162	0.000962	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000161	0.000958	CbGpPWpGaD
Fulvestrant—Nausea—Methotrexate—psoriasis	0.000156	0.00032	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000155	0.000922	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—VDR—psoriasis	0.000154	0.000919	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—APOE—psoriasis	0.000151	0.000898	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CAT—psoriasis	0.000142	0.000845	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000141	0.000837	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPARG—psoriasis	0.000132	0.000783	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—CARM1—psoriasis	0.00013	0.000776	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—psoriasis	0.000128	0.000763	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PPARG—psoriasis	0.000124	0.000735	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	0.000121	0.000717	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IL6—psoriasis	0.000117	0.000695	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PPARG—psoriasis	0.000113	0.000671	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—APOE—psoriasis	0.00011	0.000657	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PPARG—psoriasis	0.000108	0.00064	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	0.000106	0.000632	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL20—psoriasis	9.97e-05	0.000593	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PPARG—psoriasis	9.61e-05	0.000572	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NDUFA5—psoriasis	7.96e-05	0.000474	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—VDR—psoriasis	7.79e-05	0.000463	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP2S1—psoriasis	6.77e-05	0.000403	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SOCS1—psoriasis	5.49e-05	0.000327	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PPARG—psoriasis	5.43e-05	0.000323	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—APOE—psoriasis	4.05e-05	0.000241	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LEP—psoriasis	4.05e-05	0.000241	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NFKBIA—psoriasis	3.78e-05	0.000225	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CARM1—psoriasis	3.3e-05	0.000197	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TYK2—psoriasis	3.09e-05	0.000184	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCL8—psoriasis	2.69e-05	0.00016	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JUN—psoriasis	2.5e-05	0.000149	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NFKB1—psoriasis	2.41e-05	0.000143	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—psoriasis	2.19e-05	0.00013	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT3—psoriasis	2.17e-05	0.000129	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CAT—psoriasis	2.03e-05	0.000121	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—psoriasis	1.65e-05	9.83e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—APOE—psoriasis	1.58e-05	9.4e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6—psoriasis	1.51e-05	9e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPARG—psoriasis	1.38e-05	8.19e-05	CbGpPWpGaD
